520.57
-6.09 (-1.16%)
| Previous Close | 526.66 |
| Open | 517.00 |
| Volume | 471,703 |
| Avg. Volume (3M) | 628,256 |
| Market Cap | 41,865,232,384 |
| Price / Earnings (TTM) | 48.07 |
| Price / Earnings (Forward) | 51.28 |
| Price / Sales | 13.16 |
| Price / Book | 35.49 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 |
| Profit Margin | 22.76% |
| Operating Margin (TTM) | 31.70% |
| Diluted EPS (TTM) | 10.82 |
| Quarterly Revenue Growth (YOY) | 3.60% |
| Quarterly Earnings Growth (YOY) | 3.00% |
| Total Debt/Equity (MRQ) | 73.16% |
| Current Ratio (MRQ) | 1.16 |
| Operating Cash Flow (TTM) | 968.38 M |
| Levered Free Cash Flow (TTM) | 761.15 M |
| Return on Assets (TTM) | 22.98% |
| Return on Equity (TTM) | 59.33% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | IDEXX Laboratories, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | 0.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.5 |
| Average | 1.40 |
|
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.67% |
| % Held by Institutions | 97.51% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 765.00 (Morgan Stanley, 46.95%) | Buy |
| Median | 675.00 (29.67%) | |
| Low | 540.00 (Stifel, 3.73%) | Hold |
| Average | 656.00 (26.02%) | |
| Total | 3 Buy, 2 Hold | |
| Avg. Price @ Call | 609.43 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 15 Aug 2025 | 765.00 (46.95%) | Buy | 650.84 |
| Piper Sandler | 11 Aug 2025 | 700.00 (34.47%) | Hold | 652.11 |
| JP Morgan | 04 Aug 2025 | 675.00 (29.67%) | Buy | 682.78 |
| Leerink Partners | 17 Jul 2025 | 600.00 (15.26%) | Buy | 518.71 |
| 11 Jun 2025 | 580.00 (11.42%) | Buy | 524.18 | |
| Stifel | 02 Jul 2025 | 540.00 (3.73%) | Hold | 542.71 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| SZOSTAK M ANNE | 645.55 | 645.55 | -2,187 | -1,411,818 |
| Aggregate Net Quantity | -2,187 | |||
| Aggregate Net Value ($) | -1,411,818 | |||
| Aggregate Avg. Buy ($) | 645.55 | |||
| Aggregate Avg. Sell ($) | 645.55 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SZOSTAK M ANNE | Director | 22 Aug 2025 | Sell (-) | 2,187 | 645.55 | 1,411,818 |
| SZOSTAK M ANNE | Director | 22 Aug 2025 | Disposed (-) | 259 | 645.55 | 167,197 |
| SZOSTAK M ANNE | Director | 22 Aug 2025 | Acquired (+) | 259 | 645.55 | 167,197 |
| SZOSTAK M ANNE | Director | 22 Aug 2025 | Option execute | 2,187 | - | - |
| Date | Type | Details |
|---|---|---|
| 04 Aug 2025 | Announcement | IDEXX Laboratories Announces Second Quarter Results |
| 30 Jul 2025 | Announcement | IDEXX Releases 2024 Corporate Responsibility Report, Highlighting Progress Against Its Goals |
| 10 Jul 2025 | Announcement | IDEXX Laboratories Elects Joseph L. (Jay) Hooley to Board of Directors |
| 24 Jun 2025 | Announcement | IDEXX Laboratories to Release 2025 Second Quarter Financial Results |
| 05 Jun 2025 | Announcement | Third Expansion of IDEXX's Catalyst Platform in Under a Year Delivers Critical Insights to Veterinarians Evaluating Canine Patients for Endocrine Disorders |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |